FI4116301T3 - Fuusioitunut trisyklinen yhdiste ja sen lääkinnällinen käyttö - Google Patents
Fuusioitunut trisyklinen yhdiste ja sen lääkinnällinen käyttöInfo
- Publication number
- FI4116301T3 FI4116301T3 FIEP21764169.5T FI21764169T FI4116301T3 FI 4116301 T3 FI4116301 T3 FI 4116301T3 FI 21764169 T FI21764169 T FI 21764169T FI 4116301 T3 FI4116301 T3 FI 4116301T3
- Authority
- FI
- Finland
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- acceptable salt
- alkyl
- halogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11002—[Pyruvate dehydrogenase (acetyl-transferring)] kinase (2.7.11.2)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020036931 | 2020-03-04 | ||
| JP2021001452 | 2021-01-07 | ||
| PCT/JP2021/008055 WO2021177330A1 (ja) | 2020-03-04 | 2021-03-03 | 縮合三環性化合物及びその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4116301T3 true FI4116301T3 (fi) | 2025-12-19 |
Family
ID=77613417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21764169.5T FI4116301T3 (fi) | 2020-03-04 | 2021-03-03 | Fuusioitunut trisyklinen yhdiste ja sen lääkinnällinen käyttö |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20230025880A1 (https=) |
| EP (2) | EP4663189A3 (https=) |
| JP (2) | JP7739012B2 (https=) |
| KR (1) | KR20220149688A (https=) |
| CN (1) | CN115151543B (https=) |
| AU (1) | AU2021230880A1 (https=) |
| BR (1) | BR112022014749A2 (https=) |
| CA (1) | CA3166747A1 (https=) |
| CL (1) | CL2022002355A1 (https=) |
| CO (1) | CO2022012548A2 (https=) |
| DK (1) | DK4116301T3 (https=) |
| ES (1) | ES3052010T3 (https=) |
| FI (1) | FI4116301T3 (https=) |
| HR (1) | HRP20251364T1 (https=) |
| IL (1) | IL295836B2 (https=) |
| LT (1) | LT4116301T (https=) |
| MX (1) | MX2022010950A (https=) |
| PE (1) | PE20221908A1 (https=) |
| PH (1) | PH12022552259A1 (https=) |
| PL (1) | PL4116301T3 (https=) |
| PT (1) | PT4116301T (https=) |
| RS (1) | RS67408B1 (https=) |
| SI (1) | SI4116301T1 (https=) |
| SM (1) | SMT202500464T1 (https=) |
| TW (1) | TWI884224B (https=) |
| WO (1) | WO2021177330A1 (https=) |
| ZA (1) | ZA202209620B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114237A1 (es) * | 2018-02-01 | 2020-08-05 | Japan Tobacco Inc | Compuesto de amida heterocíclica que contiene nitrógeno y su uso farmacéutico |
| PL4116301T3 (pl) * | 2020-03-04 | 2026-02-16 | Japan Tobacco Inc. | Skondensowany związek tricykliczny i jego zastosowanie medyczne |
| AU2022337617A1 (en) * | 2021-09-01 | 2024-04-18 | Japan Tobacco Inc. | Nitrogen-containing tricyclic compound and pharmaceutical use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1615647B1 (en) * | 2003-04-11 | 2010-01-20 | High Point Pharmaceuticals, LLC | Pharmaceutical use of fused 1,2,4-triazoles |
| US20050085531A1 (en) * | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| KR100808551B1 (ko) * | 2006-12-01 | 2008-03-03 | 한국생명공학연구원 | 트리아졸 유도체를 유효성분으로 함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
| BR112015022077A2 (pt) * | 2013-03-15 | 2017-07-18 | Japan Tobacco Inc | composto de pirazol-amida e usos medicinais do mesmo |
| EP3328857B1 (en) * | 2015-07-31 | 2019-08-14 | Merck Patent GmbH | Bicyclic heterocyclic derivatives |
| AR114237A1 (es) * | 2018-02-01 | 2020-08-05 | Japan Tobacco Inc | Compuesto de amida heterocíclica que contiene nitrógeno y su uso farmacéutico |
| CN112638377A (zh) | 2018-09-11 | 2021-04-09 | 日本烟草产业株式会社 | 含有吡唑酰胺化合物的慢性肾脏病的治疗或预防剂 |
| PL4116301T3 (pl) | 2020-03-04 | 2026-02-16 | Japan Tobacco Inc. | Skondensowany związek tricykliczny i jego zastosowanie medyczne |
-
2021
- 2021-03-03 PL PL21764169.5T patent/PL4116301T3/pl unknown
- 2021-03-03 CA CA3166747A patent/CA3166747A1/en active Pending
- 2021-03-03 EP EP25206111.4A patent/EP4663189A3/en active Pending
- 2021-03-03 MX MX2022010950A patent/MX2022010950A/es unknown
- 2021-03-03 DK DK21764169.5T patent/DK4116301T3/da active
- 2021-03-03 FI FIEP21764169.5T patent/FI4116301T3/fi active
- 2021-03-03 EP EP21764169.5A patent/EP4116301B1/en active Active
- 2021-03-03 ES ES21764169T patent/ES3052010T3/es active Active
- 2021-03-03 WO PCT/JP2021/008055 patent/WO2021177330A1/ja not_active Ceased
- 2021-03-03 PE PE2022001891A patent/PE20221908A1/es unknown
- 2021-03-03 TW TW110107548A patent/TWI884224B/zh active
- 2021-03-03 LT LTEPPCT/JP2021/008055T patent/LT4116301T/lt unknown
- 2021-03-03 RS RS20251131A patent/RS67408B1/sr unknown
- 2021-03-03 IL IL295836A patent/IL295836B2/en unknown
- 2021-03-03 CN CN202180018517.1A patent/CN115151543B/zh active Active
- 2021-03-03 PH PH1/2022/552259A patent/PH12022552259A1/en unknown
- 2021-03-03 SM SM20250464T patent/SMT202500464T1/it unknown
- 2021-03-03 AU AU2021230880A patent/AU2021230880A1/en active Pending
- 2021-03-03 HR HRP20251364TT patent/HRP20251364T1/hr unknown
- 2021-03-03 BR BR112022014749A patent/BR112022014749A2/pt unknown
- 2021-03-03 PT PT217641695T patent/PT4116301T/pt unknown
- 2021-03-03 KR KR1020227032125A patent/KR20220149688A/ko active Pending
- 2021-03-03 JP JP2021033150A patent/JP7739012B2/ja active Active
- 2021-03-03 US US17/602,103 patent/US20230025880A1/en active Pending
- 2021-03-03 SI SI202130359T patent/SI4116301T1/sl unknown
-
2022
- 2022-08-29 CL CL2022002355A patent/CL2022002355A1/es unknown
- 2022-08-29 ZA ZA2022/09620A patent/ZA202209620B/en unknown
- 2022-09-01 CO CONC2022/0012548A patent/CO2022012548A2/es unknown
-
2025
- 2025-09-03 JP JP2025145992A patent/JP2025175000A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4116301T3 (fi) | Fuusioitunut trisyklinen yhdiste ja sen lääkinnällinen käyttö | |
| JP6907173B2 (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| CA2798610A1 (en) | Bicyclic heteroaryl compounds as gpr119 modulators | |
| JP2023529354A5 (https=) | ||
| JP2013523763A5 (https=) | ||
| HRP20120476T1 (hr) | Derivati 4-benzilamino-1-karboksiacil-piperidina kao cetp inhibitori korisni za liječenje bolesti kao što su hiperlipidemija ili arterioskleroza | |
| HRP20201927T1 (hr) | PIRIMIDINONI KAO INHIBITORI FAKTORA XIa | |
| NZ595073A (en) | Proline derivatives as cathepsin inhibitors | |
| ZA200610138B (en) | Factor Xa inhibitors | |
| EA201071090A1 (ru) | Модуляторы рецептора простациклина (pgi2), пригодные для лечения связанных с ним расстройств | |
| SI2966067T1 (en) | OKSAZEPINI AS ION CHANNEL MODULATORS | |
| ME02557B (me) | Fuzionisani biciklicni oksazoliidinon kao inhibitor cetp | |
| JPWO2019013311A5 (https=) | ||
| AR035057A1 (es) | Compuestos de n-hidroxi-3-fenil-2e-2-propenamida, composiciones farmaceuticas y el uso de dichos compuestos para la manufactura de un medicamento para un desorden proliferativo | |
| KR950702967A (ko) | 약제학적 활성 디케토피페라진(Pharmaceutically active diketopiperazines) | |
| CA2437587A1 (en) | Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazolines and their use as anticoagulant and antithrombotic agents | |
| JP2019510794A5 (https=) | ||
| JP2022007994A5 (https=) | ||
| JP2019131544A5 (https=) | ||
| IL320810A (en) | Glucagon-like peptide 1 receptor agonists | |
| JP2024523313A5 (https=) | ||
| FI3814331T3 (fi) | Uusia LXR-modulaattoreita, joissa on bisyklinen ydin | |
| RU2015150287A (ru) | Новые соединения 3,4-дигидро-2н-изохинолин-1-она и 2,3-дигидроизоиндол-1-она | |
| AR057849A1 (es) | Dialurrea para el tratamiento de hipertension pulmonar | |
| RU2011103766A (ru) | Ингибиторы fxa с циклическим амидоксимом или циклическим амидразоном в качестве p4 субъединицы, способы их получения и их фармацевтические композиции и производные |